Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EDIT vs TWST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TWST Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–2 Matrix Metrics)

TWST Overall Winner 6-Pillar Tally: EDIT 2 – 4 TWST Matrix Metrics: EDIT 2 – 5 TWST

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Editas Medicine, Inc. (EDIT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.85 (N/M Forward P/E, -31.9% operating margin).

  • Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EDIT vs TWST
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $2.52 · SMA50: $2.61
TWST NASDAQ Head-to-Head Winner
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.85
-5.15% 1D
Market Cap $7.6B
TTM Revenue $432M
Forward P/E N/M
Beta / 30D Vol 3.15β · 127% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.9 · SMA20: $137.33 · SMA50: $149.84

6-Pillar Scorecard Institutional Category Breakdown (EDIT 2 – 4 TWST)

Columns: Metric · EDIT · TWST
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 5.2x 17.5x
2. Growth & Scale TWST
Revenue Growth (YoY) +37.4% +23.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $50M $432M
Market Cap $336.5M $7.6B
3. Profitability & Quality TWST
Gross Margin -73.3% 52.0%
Operating Margin -167.0% -31.9%
Net Profit Margin -144.9% -31.7%
Return on Equity (ROE) -147.4% -29.6%
4. Balance Sheet & Cash Flow TWST
Cash Generation (TTM) -$110M -$115M EBITDA
Cash Flow Margin N/A -26.7% EBITDA Mgn
Net Cash / Leverage $79M Net Cash $7.11 Book/Sh · -29.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 95.8% (38th %ile) 93.2% (18th %ile)
Put/Call OI Skew 0.29x (Call-Skewed) 1.04x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity N/A 83.9% of Rev ($362M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EDIT (2) vs TWST (5)
Institutional Metric EDIT TWST Criterion Row Edge
Market Capitalization
Scale
$336.5M $7.6B Larger Scale TWST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+37.4% +23.2% Higher Growth EDIT
Operating Margin (TTM)
Profitability
-167.0% -31.9% Higher Margin TWST
Net Profit Margin
Profitability
-144.9% -31.7% Higher Margin TWST
Return on Equity (ROE)
Capital Efficiency
-147.4% -29.6% Higher ROE TWST
52-Week Range Position
Momentum
11% ($2–$4) 42% ($23–$220) Stronger Trend TWST
Beta / 30D Volatility
Risk Regime
2.32β · 102% Vol 3.15β · 127% Vol Lower Realized Risk EDIT
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 51.7 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$50M $432M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-73.3% 52.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.2x EV/Rev N/M PEG · 17.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($79M Net Cash) -$115M EBITDA ($7.11 Book/Sh · -29.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EDIT +1.32 pp
EDIT: -18.94% · TWST: -20.26%
3M Horizon TWST +25.02 pp
EDIT: -33.85% · TWST: -8.83%
6M Horizon TWST +137.29 pp
EDIT: -24.7% · TWST: +112.59%
1Y Horizon TWST +279.01 pp
EDIT: -25.0% · TWST: +254.01%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EDIT Revenue TWST Revenue EDIT Op. Margin TWST Op. Margin Margin Leader
FY2018 $30M $30M -356.1% -277.5% TWST
FY2019 $20M $50M -686.4% -200.1% TWST
FY2020 $90M $90M -148.6% -155.5% EDIT
FY2021 $30M $130M -756.1% -115.4% TWST
FY2022 $20M $200M -1146.3% -115.3% TWST
FY2023 $80M $250M -216.6% -88.6% TWST
FY2024 $30M $310M -777.2% -70.6% TWST
FY2025 $40M $380M -394.9% -36.2% TWST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 93.2%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.6B market capitalization and -31.9% operating margin.
OpEx & R&D Reinvestment 83.9% of Rev ($362M)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ EDIT vs TWST Key Questions & Quantitative Answers

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Editas Medicine, Inc. (EDIT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.85 (N/M Forward P/E, -31.9% operating margin). Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TWST leads the Growth & Scale pillar: EDIT posts +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin), compared with TWST at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $432M TTM revenue (52.0% gross margin, -31.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EDIT cumulative revenue shifted +33.3% while TWST shifted +1166.7%. In operating R&D and SG&A reinvestment, EDIT deploys N/A (0 90-day corporate R&D disclosures) versus 83.9% of Rev ($362M) (0 disclosures) for TWST.

EDIT screens cheaper on headline valuation multiples. EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.5x EV/Revenue (-26.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDIT (-147.4% ROE) versus TWST (-29.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk). By comparison, TWST carries 93.2% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.15β · 127% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.